Bristol Myers Squibb Company - BMY Earnings per share for the last 12 months

Public company logo of Bristol Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) focuses on the global targeted therapy market, refreshing its portfolio through the acquisition of startups. Its status as a recognized innovator in immunology strengthens physician confidence. A year-over-year EPS (TTM) comparison confirms the business's resilience, where the value of 52.80 characterizes this level. However, the expiration of patents on key drugs is temporarily reducing the holding's overall margins.

BMY Bristol Myers Squibb Company: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

Bristol-Myers Squibb - analytical breakdowns and key metrics (BMY)

Initial company analysis:Bristol Myers Squibb BMY
Signature product of Bristol-Myers Squibb Co.

Bristol-Myers Squibb (BMY) resilience to market volatility is driven by stable demand for patented oncology and cardiovascular therapies. The profitability dynamics of this business are reflected in the 12-month YoY EPS trend, which smooths quarterly gaps via a rolling annual window. This metric measures the actual growth in net income per share while neutralizing reporting seasonality. Investors should note that even with a positive trend, high borrowing costs may exert pressure on capital margins.